Vericel to Present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021

Rhea-AI Summary

Vericel Corporation (NASDAQ:VCEL) announced that Nick Colangelo, President and CEO, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 11:40 a.m. Eastern Time. This virtual conference will showcase an overview of the company, renowned for its advanced therapies in sports medicine and severe burn care. A live webcast of the presentation can be accessed on the Investor Relations section of Vericel's website.

CAMBRIDGE, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the 39^th Annual J.P. Morgan Healthcare Conference. The conference is being conducted in a virtual format and the presentation will take place on Thursday, January 14, 2021 at 11:40 a.m. Eastern Time.

A live webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI^® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel^® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid^®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit the company’s website at www.vcel.com.

Epicel^® and MACI^® are registered trademarks of Vericel Corporation. NexoBrid^® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2020 Vericel Corporation. All rights reserved.

Investor Contacts:
Chad Rubin
Solebury Trout
crubin@troutgroup.com
+1 646-378-2947

FAQ

What time is Vericel's presentation at the J.P. Morgan Healthcare Conference?

Vericel's presentation is scheduled for January 14, 2021, at 11:40 a.m. Eastern Time.

How can I watch Vericel's presentation at the healthcare conference?

You can watch the presentation live on the Investor Relations section of Vericel's website.

Who will present at the 39th Annual J.P. Morgan Healthcare Conference for VCEL?

Nick Colangelo, President and CEO of Vericel, will present at the conference.

What products does Vericel Corporation market for sports medicine and burn care?

Vericel markets two products: MACI® for cartilage repair and Epicel® for skin replacement in burn treatment.

What is the date of the 39th Annual J.P. Morgan Healthcare Conference?

The conference will take place on January 14, 2021.